GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Brainstorm Cell Therapeutics Inc (FRA:GHDN) » Definitions » Cyclically Adjusted PB Ratio

Brainstorm Cell Therapeutics (FRA:GHDN) Cyclically Adjusted PB Ratio : 0.90 (As of Jun. 06, 2024)


View and export this data going back to . Start your Free Trial

What is Brainstorm Cell Therapeutics Cyclically Adjusted PB Ratio?

As of today (2024-06-06), Brainstorm Cell Therapeutics's current share price is €0.3945. Brainstorm Cell Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €0.44. Brainstorm Cell Therapeutics's Cyclically Adjusted PB Ratio for today is 0.90.

The historical rank and industry rank for Brainstorm Cell Therapeutics's Cyclically Adjusted PB Ratio or its related term are showing as below:

FRA:GHDN' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 1.51
Current: 0.9

During the past years, Brainstorm Cell Therapeutics's highest Cyclically Adjusted PB Ratio was 1.51. The lowest was 0.00. And the median was 0.00.

FRA:GHDN's Cyclically Adjusted PB Ratio is ranked better than
64.75% of 661 companies
in the Biotechnology industry
Industry Median: 1.75 vs FRA:GHDN: 0.90

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Brainstorm Cell Therapeutics's adjusted book value per share data for the three months ended in Mar. 2024 was €-0.075. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €0.44 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Brainstorm Cell Therapeutics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Brainstorm Cell Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Brainstorm Cell Therapeutics Cyclically Adjusted PB Ratio Chart

Brainstorm Cell Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.40 10.79 8.09 3.22 0.57

Brainstorm Cell Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.55 4.12 0.41 0.57 1.17

Competitive Comparison of Brainstorm Cell Therapeutics's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Brainstorm Cell Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Brainstorm Cell Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Brainstorm Cell Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Brainstorm Cell Therapeutics's Cyclically Adjusted PB Ratio falls into.



Brainstorm Cell Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Brainstorm Cell Therapeutics's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=0.3945/0.44
=0.90

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Brainstorm Cell Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Brainstorm Cell Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.075/131.7762*131.7762
=-0.075

Current CPI (Mar. 2024) = 131.7762.

Brainstorm Cell Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201406 0.519 100.560 0.680
201409 0.454 100.428 0.596
201412 0.354 99.070 0.471
201503 0.988 99.621 1.307
201506 0.860 100.684 1.126
201509 0.748 100.392 0.982
201512 0.696 99.792 0.919
201603 0.605 100.470 0.794
201606 0.566 101.688 0.733
201609 0.502 101.861 0.649
201612 0.502 101.863 0.649
201703 0.412 102.862 0.528
201706 0.346 103.349 0.441
201709 0.231 104.136 0.292
201712 0.262 104.011 0.332
201803 0.163 105.290 0.204
201806 0.533 106.317 0.661
201809 0.413 106.507 0.511
201812 0.212 105.998 0.264
201903 0.013 107.251 0.016
201906 -0.184 108.070 -0.224
201909 -0.272 108.329 -0.331
201912 -0.475 108.420 -0.577
202003 0.287 108.902 0.347
202006 0.294 108.767 0.356
202009 0.699 109.815 0.839
202012 0.829 109.897 0.994
202103 0.837 111.754 0.987
202106 0.690 114.631 0.793
202109 0.584 115.734 0.665
202112 0.470 117.630 0.527
202203 0.361 121.301 0.392
202206 0.204 125.017 0.215
202209 0.038 125.227 0.040
202212 -0.078 125.222 -0.082
202303 -0.118 127.348 -0.122
202306 -0.088 128.729 -0.090
202309 -0.053 129.860 -0.054
202312 -0.074 129.419 -0.075
202403 -0.075 131.776 -0.075

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Brainstorm Cell Therapeutics  (FRA:GHDN) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Brainstorm Cell Therapeutics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Brainstorm Cell Therapeutics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Brainstorm Cell Therapeutics (FRA:GHDN) Business Description

Traded in Other Exchanges
Address
1325 Avenue of Americas, 28th Floor, New York, NY, USA, 10019
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.

Brainstorm Cell Therapeutics (FRA:GHDN) Headlines

No Headlines